DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme

BJU International

Volumn 105, Issue 3, 2010, Pages 329-333

  Isharwal, Sumit ^a   Makarov, Danil V ^a   Carter, H Ballentine ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Landis, Patricia ^a   Marlow, Cameron ^a   Veltri, Robert W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign adjacent; Cancer; DNA content; Expectant management; Prediction; Prostate cancer; Unfavourable biopsy conversion

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER TISSUE; DIAGNOSTIC TEST; DNA CONTENT; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPTICAL DENSITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; STAINING;

AGED; BIOPSY, NEEDLE; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 75149141383     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08791.x     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58: 71 96
2. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95: 868 878
3. Carter HB, Kettermann A, Warlick C et al. Expectant management of prostate cancer with curative intent. An update of the Johns Hopkins experience. J Urol 2007 178: 2359 2364
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271: 368 374
5. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995 153: 1015 1019
6. Veltri RW, Partin AW, Epstein JE et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cellular Biochem 1994 19: 249 258
7. Isharwal S, Miller MC, Epstein JI et al. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer 2008 123: 2636 2643
8. Martinez-Jabaloyas JM, Ruiz-Cerda JL, Hernandez M, Jimenez A, Jimenez-Cruz F. Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. Urology 2002 59: 715 720
9. Sebo TJ, Cheville JC, Riehle DL et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001 91: 2196 2204
10. Ross JS, Sheehan CE, Ambros RA et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 1999 23: 296 301
11. Tribukait B. Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas. Clinical research applications. Eur Urol 1993 23 (Suppl. 2 64 76
12. Adolfsson J, Tribukait B, Levitt S. The 20-Yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 2007 52: 1028 1035
13. Veltri RW, Khan MA, Miller MC et al. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004 10: 3465 3473
14. Veltri RW, Khan MA, Marlow C et al. Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer. Urology 2006 68: 898 904
15. Gill JE, Jotz MM. Further observations on the chemistry of pararosaniline-Feulgen staining. Histochemistry 1976 46: 147 160
16. Schulte E, Wittekind D. Standardization of the Feulgen-Schiff technique. Staining characteristics of pure fuchsin dyes; a cytophotometric investigation. Histochemistry 1989 91: 321 331
17. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008 100: 1144 1154
18. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006 98: 355 357
19. Deitch AD, Miller GJ, deVere White RW. Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue. Cancer 1993 72: 1692 1700
20. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005 5: 45
21. Parr RL, Dakubo GD, Crandall KA et al. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006 8: 312 319
22. Isharwal S, Miller MC, Epstein JI et al. DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology 2009 73: 1092 1097
23. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results: from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007 120: 170 174
24. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000 164: 716 721
25. Jhavar S, Bartlett J, Kovacs G et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 2009 12: 143 147
26. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998 78: 940 944
27. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000 6: 1882 1890
28. Demichelis F, Fall K, Perner S et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007 26: 4596 4599